ISORDIL (isosorbide dinitrate) by Bausch + Lomb. Approved for nitrate vasodilator [epc]. First approved in 1959.
Drug data last refreshed 16h ago · AI intelligence enriched 3d ago
ISORDIL (isosorbide dinitrate) is an oral nitrate vasodilator approved in 1959 for the treatment of angina pectoris and heart failure. It works by relaxing vascular smooth muscle and reducing preload and afterload on the heart. The drug remains a foundational therapy in cardiovascular disease management.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (60/100), the brand team is likely focused on defending market share against generics rather than growth initiatives.
Nitrate Vasodilator
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ISORDIL offers experience in late-stage product management, generic defense strategies, and cardiovascular market dynamics, but limited opportunity for innovation or career acceleration. This role is best suited for professionals seeking stability in a mature market or developing expertise in formulary negotiations and customer retention.
Worked on ISORDIL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.